Iterative Health Adds Hepatology and Obesity Specialist as Chief Medical Officer
Event summary
- Iterative Health appointed Nadege Gunn, MD, as Chief Medical Officer for Hepatology and Obesity on February 12, 2026.
- Dr. Gunn brings over 15 years of experience in clinical trials and specialized expertise in metabolic liver disease and obesity.
- She previously founded and led the Impact Research Institute, a leading hepatology research center.
- Iterative Health also promoted Dana Feuchtbaum to Chief Operating Officer.
The big picture
Iterative Health’s appointment of Dr. Gunn underscores its commitment to expanding its therapeutic focus areas and strengthening clinical leadership in hepatology and obesity research. This move aligns with the broader industry trend of leveraging specialized medical expertise to accelerate the development of novel therapies, particularly in metabolic liver disease and obesity.
What we're watching
- Clinical Trial Expansion
- How Iterative Health will leverage Dr. Gunn’s expertise to accelerate hepatology and obesity research at scale.
- Strategic Partnerships
- Whether the appointment strengthens Iterative Health’s collaborations with biopharmaceutical sponsors and CRO partners.
- Operational Efficiency
- The pace at which Dana Feuchtbaum’s promotion to COO enhances global site network operations across four continents.